STAAR appoints David Bailey as chief commercial officer
He returns to lead commercial strategy following his prior tenure as president and CEO, focusing on EVO ICL expansion against declining laser refractive procedures.
See the latest news and media coverage for STAAR. We track all announcements, press releases, and industry mentions in real time, all in one place.
Ophthalmic implant and surgical delivery system manufacturer
staar.comLast updated
In short: STAAR posted strong 2026 results, named a permanent CEO, and rejected Alcon's $1.5B takeover to remain standalone.
He returns to lead commercial strategy following his prior tenure as president and CEO, focusing on EVO ICL expansion against declining laser refractive procedures.
Park joins from Align Technology to lead R&D, advancing the company's strategy to evolve into a multi-product innovation platform beyond its single-product focus.
Net sales up 111% year-over-year, net income of $8.1M, adjusted EBITDA of $20.0M. Growth driven by China market share gains and EVO+ launch.
Warren Foust, previously COO and interim co-CEO, now joins the board; Deborah Andrews, interim co-CEO, becomes EVP while remaining CFO.
STAAR intends to fund its share repurchases using organic free cash flow and cash on hand. As of July 3, 2026, the Company had no...
/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of...
The STAAR Surgical stock was trading at $24.43 on September 22, 2026, which is 3.7 percent below the previous closing price. For investors, a new analyst rating is also available in...
Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a...
Track STAAR and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to STAAR and other trending companies.